New River Pharmaceuticals Inc. ("NRPH") is a specialty pharmaceutical company developing novel pharmaceuticals that are generational improvements of widely-prescribed drugs in large and growing markets. We are developing new molecular entities that are derivatives of public domain actives using our proprietary Carrierwave™ technology.

Our lead product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that we believe will provide improved alternatives to currently marketed drugs. In preclinical development, we are researching a drug for the treatment of chronic pain, which we believe could reduce the development of opioid tolerance, and a drug for the treatment of primary hypothyroidism.